• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根治性切除治疗无大血管侵犯的单发巨块型肝细胞癌患者的长期疗效及预后因素分析。

Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors.

机构信息

Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University, 651 Dongfeng Road East, Guangzhou, 510060, People's Republic of China.

出版信息

Med Oncol. 2013 Dec;30(4):696. doi: 10.1007/s12032-013-0696-3. Epub 2013 Aug 22.

DOI:10.1007/s12032-013-0696-3
PMID:23975633
Abstract

The long-term outcome and prognostic factors after curative in patients with single hepatocellular carcinoma (HCC) without macrovascular invasion are still unclear. The objective of this study is to evaluate the effect of curative resection on survival and analyze the prognostic clinicopathologic factors, especially the presence of microvascular invasion (MVI), in these patients. Two hundred and sixty consecutive patients with single HCC without macrovascular invasion who underwent curative resection from December 2004 to December 2007 were retrospectively reviewed in this study. Survival rates were calculated by using the Kaplan-Meier method. Univariate and multivariate analyses of 14 clinicopathologic factors were performed to determine the significant prognostic factors. No patient died within 1 month after the operation. The 1-, 3-, and 5-year overall survival rates after curative resection were 96.54, 83.46, and 74.01%, respectively. Multivariate analysis revealed that only the presence of MVI was an independent negative prognostic factor affecting overall survival. The 1-, 3-, and 5-year disease-free survival rates were 79.62, 62.69, and 56.01%, respectively. The presence of MVI was the only independent unfavorable prognostic factor for disease-free survival. According to our analysis, patients with single HCC without macrovascular invasion after curative resection can be expected to have considerable long-term survival. The presence of MVI was an independent negative prognostic factor for both overall survival and disease-free survival. To improve the prognosis, these patients should be followed up more carefully and might be good candidates for adjuvant therapy.

摘要

在没有大血管侵犯的单发性肝细胞癌 (HCC) 患者中,根治性切除术后的长期预后和预测因素仍不清楚。本研究的目的是评估根治性切除对生存的影响,并分析这些患者的临床病理预后因素,特别是微血管侵犯 (MVI) 的存在。本研究回顾性分析了 2004 年 12 月至 2007 年 12 月期间接受根治性切除的 260 例无大血管侵犯的单发性 HCC 患者。采用 Kaplan-Meier 法计算生存率。对 14 项临床病理因素进行单因素和多因素分析,确定显著的预后因素。术后 1 个月内无患者死亡。根治性切除术后 1、3 和 5 年总生存率分别为 96.54%、83.46%和 74.01%。多因素分析显示,只有 MVI 的存在是影响总生存的独立负预后因素。无复发生存率分别为 79.62%、62.69%和 56.01%。MVI 的存在是无复发生存的唯一独立不良预后因素。根据我们的分析,根治性切除术后无大血管侵犯的单发性 HCC 患者有望获得相当长的长期生存。MVI 的存在是总生存和无复发生存的独立负预后因素。为了改善预后,这些患者应更密切地随访,并且可能是辅助治疗的良好候选者。

相似文献

1
Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors.根治性切除治疗无大血管侵犯的单发巨块型肝细胞癌患者的长期疗效及预后因素分析。
Med Oncol. 2013 Dec;30(4):696. doi: 10.1007/s12032-013-0696-3. Epub 2013 Aug 22.
2
The impact of resection margin and microvascular invasion on long-term prognosis after curative resection of hepatocellular carcinoma: a multi-institutional study.根治性切除术后切缘和微血管侵犯对肝癌长期预后的影响:多机构研究。
HPB (Oxford). 2019 Aug;21(8):962-971. doi: 10.1016/j.hpb.2018.11.005. Epub 2019 Feb 2.
3
The Impact of Tumor Size on Long-Term Survival Outcomes After Resection of Solitary Hepatocellular Carcinoma: Single-Institution Experience with 2558 Patients.肿瘤大小对孤立性肝细胞癌切除术后长期生存结果的影响:单机构2558例患者的经验
J Gastrointest Surg. 2015 Jul;19(7):1281-90. doi: 10.1007/s11605-015-2849-5. Epub 2015 May 9.
4
Microvascular invasion and positive HB e antigen are associated with poorer survival after hepatectomy of early hepatocellular carcinoma: A retrospective cohort study.微血管侵犯和乙肝e抗原阳性与早期肝细胞癌肝切除术后较差的生存率相关:一项回顾性队列研究。
Clin Res Hepatol Gastroenterol. 2018 Sep;42(4):330-338. doi: 10.1016/j.clinre.2018.02.003. Epub 2018 Mar 16.
5
Impact of preoperative TACE on incidences of microvascular invasion and long-term post-hepatectomy survival in hepatocellular carcinoma patients: A propensity score matching analysis.术前 TACE 对肝细胞癌患者微血管侵犯发生率和长期肝切除术后生存的影响:倾向评分匹配分析。
Cancer Med. 2021 Mar;10(6):2100-2111. doi: 10.1002/cam4.3814. Epub 2021 Mar 1.
6
Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors.肝细胞癌患者的微血管侵犯及其可预测的临床病理因素。
Ann Surg Oncol. 2008 May;15(5):1375-82. doi: 10.1245/s10434-008-9846-9. Epub 2008 Mar 7.
7
Prognostic value of a novel risk classification of microvascular invasion in patients with hepatocellular carcinoma after resection.切除术后肝细胞癌患者微血管侵犯新风险分类的预后价值
Oncotarget. 2017 Jan 17;8(3):5474-5486. doi: 10.18632/oncotarget.12547.
8
Microvascular invasion (MVI) is a poorer prognostic predictor for small hepatocellular carcinoma.微血管侵犯(MVI)是小肝细胞癌预后较差的预测指标。
BMC Cancer. 2014 Jan 24;14:38. doi: 10.1186/1471-2407-14-38.
9
Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.术后辅助经导管动脉化疗栓塞治疗伴微血管侵犯的肝细胞癌患者的疗效。
World J Gastroenterol. 2017 Nov 7;23(41):7415-7424. doi: 10.3748/wjg.v23.i41.7415.
10
Preoperative predictors of microvascular invasion in multinodular hepatocellular carcinoma.多结节性肝细胞癌微血管侵犯的术前预测因子。
Eur J Surg Oncol. 2013 Aug;39(8):858-64. doi: 10.1016/j.ejso.2013.04.003. Epub 2013 May 11.

引用本文的文献

1
Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors.接受介入治疗联合酪氨酸激酶抑制剂及免疫检查点抑制剂的转化治疗的乙肝相关肝细胞癌患者术后乙肝病毒再激活及其对生存的影响
Front Cell Infect Microbiol. 2025 Jul 17;15:1598193. doi: 10.3389/fcimb.2025.1598193. eCollection 2025.
2
Efficacy and safety of postoperative adjuvant HAIC with FOLFOX combining PD-1 inhibitors in HCC patients with microvascular invasion: a propensity score matching analysis.肝切除术后辅助性肝动脉灌注化疗联合FOLFOX方案与PD-1抑制剂治疗微血管侵犯型肝癌患者的疗效及安全性:一项倾向评分匹配分析
BMC Cancer. 2025 Mar 7;25(1):418. doi: 10.1186/s12885-025-13793-x.
3

本文引用的文献

1
Impact of hepatectomy for huge solitary hepatocellular carcinoma.巨大单发肝细胞癌行肝切除术的影响。
J Surg Oncol. 2013 Mar;107(4):408-13. doi: 10.1002/jso.23226. Epub 2012 Aug 17.
2
Liver resection for hepatocellular carcinoma ≤3 cm: results of an Italian multicenter study on 588 patients.肝切除术治疗 ≤3 cm 肝癌:意大利多中心 588 例患者研究结果。
J Am Coll Surg. 2012 Aug;215(2):244-54. doi: 10.1016/j.jamcollsurg.2012.04.013. Epub 2012 May 26.
3
Prognostic factors after liver resection for hepatocellular carcinoma: a single-center experience from China.
Portal vein tumor thrombosis in hepatocellular carcinoma patients: Is it the end?肝细胞癌患者的门静脉肿瘤血栓形成:这是终点吗?
Liver Res. 2024 Sep 7;8(3):141-151. doi: 10.1016/j.livres.2024.09.002. eCollection 2024 Sep.
4
Implanting Iodine-125 Seed Strand Inside the Portal Vein Stent: An Improved Approach to Endovascular Brachytherapy for Treatment of Patients with Hepatocellular Carcinoma and Main Portal Vein Tumor Thrombus.在门静脉支架内置入碘-125粒子链:一种用于治疗肝细胞癌合并门静脉主干癌栓患者的血管内近距离放疗的改良方法。
J Hepatocell Carcinoma. 2023 Dec 6;10:2187-2196. doi: 10.2147/JHC.S430686. eCollection 2023.
5
Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations.中国肝细胞癌动脉化疗:共识推荐
Hepatol Int. 2024 Feb;18(1):4-31. doi: 10.1007/s12072-023-10599-6. Epub 2023 Oct 21.
6
The role of F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.仑伐替尼联合 PD-1 抑制剂转换治疗不可切除 HCC 患者的 F-FDG PET 在预测病理缓解和预后中的作用。
Front Immunol. 2023 May 5;14:1151967. doi: 10.3389/fimmu.2023.1151967. eCollection 2023.
7
Hepatic arterial infusion chemotherapy versus sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: An updated meta-analysis and systematic review.肝动脉灌注化疗与索拉非尼治疗伴有门静脉癌栓的晚期肝细胞癌:一项更新的Meta分析和系统评价
Front Oncol. 2023 Jan 27;13:1085166. doi: 10.3389/fonc.2023.1085166. eCollection 2023.
8
Identification of risk and prognostic factors for intrahepatic vascular invasion in patients with hepatocellular carcinoma: a population-based study.肝细胞癌患者肝内血管侵犯的风险及预后因素识别:一项基于人群的研究。
Transl Cancer Res. 2023 Jan 30;12(1):93-112. doi: 10.21037/tcr-22-1912. Epub 2023 Jan 5.
9
Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition).中国肝细胞癌合并门静脉癌栓诊断和治疗多学科专家共识(2021年版)
Liver Cancer. 2022 Mar 17;11(4):315-328. doi: 10.1159/000523997. eCollection 2022 Jul.
10
Effect of surgical margin on postoperative prognosis in patients with solitary hepatocellular carcinoma: A propensity score matching analysis.手术切缘对孤立性肝细胞癌患者术后预后的影响:一项倾向评分匹配分析
J Cancer. 2021 May 27;12(15):4455-4462. doi: 10.7150/jca.57896. eCollection 2021.
肝癌肝切除术后的预后因素:来自中国的单中心经验。
Am J Surg. 2012 Jun;203(6):741-50. doi: 10.1016/j.amjsurg.2011.05.010. Epub 2011 Dec 15.
4
Hepatic resection for "BCLC stage A" hepatocellular carcinoma. The prognostic role of alpha-fetoprotein.肝切除术治疗“BCLC 分期 A”肝细胞癌。甲胎蛋白的预后作用。
Ann Surg Oncol. 2012 Feb;19(2):426-34. doi: 10.1245/s10434-011-1845-6. Epub 2011 Jul 6.
5
Outcome after partial hepatectomy for hepatocellular cancer within the Milan criteria.米兰标准范围内行部分肝切除术治疗肝细胞癌的结果。
Br J Surg. 2011 Sep;98(9):1292-300. doi: 10.1002/bjs.7583. Epub 2011 Jun 7.
6
Triple positive tumor markers for hepatocellular carcinoma are useful predictors of poor survival.肝癌的三重阳性肿瘤标志物是预测不良生存的有用指标。
Ann Surg. 2011 Dec;254(6):984-91. doi: 10.1097/SLA.0b013e3182215016.
7
Prognostic factors of solitary large hepatocellular carcinoma: the importance of differentiation grade.单发大肝癌的预后因素:分化程度的重要性。
Eur J Surg Oncol. 2011 Jun;37(6):521-5. doi: 10.1016/j.ejso.2011.03.137. Epub 2011 Apr 29.
8
Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma.根治性切除术后早期复发患者的预后因素。
J Surg Oncol. 2011 Feb;103(2):148-51. doi: 10.1002/jso.21786. Epub 2010 Dec 22.
9
Prognostic factors and outcome of 438 Chinese patients with hepatocellular carcinoma underwent partial hepatectomy in a single center.单中心 438 例肝细胞癌患者行部分肝切除术的预后因素和结果。
World J Surg. 2010 Oct;34(10):2434-41. doi: 10.1007/s00268-010-0664-4.
10
Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus.肝细胞癌合并门静脉癌栓的外科治疗。
Ann Surg Oncol. 2010 Aug;17(8):2073-80. doi: 10.1245/s10434-010-0940-4. Epub 2010 Feb 4.